Clinical bottom line
Pediatric eczema (atopic dermatitis) management in primary care centers on regular use of topical anti-inflammatory treatments combined with educational and psychological support to improve adherence and quality of life. Recent high-quality evidence from network meta-analyses confirms the efficacy of topical corticosteroids and calcineurin inhibitors, while structured educational interventions enhance disease control and reduce caregiver burden. Systemic therapies, including dupilumab, are emerging options for severe cases but require specialist collaboration and ongoing safety monitoring.
What the evidence shows
Lax et al. (2024) provide a comprehensive Cochrane network meta-analysis comparing topical anti-inflammatory treatments for eczema, demonstrating that topical corticosteroids remain the most effective first-line agents for reducing disease severity. Calcineurin inhibitors offer a steroid-sparing alternative with comparable efficacy, particularly useful for sensitive skin areas or long-term management.
Singleton et al. (2024) systematically reviewed educational and psychological interventions, finding that structured programs targeting both patients and caregivers improve treatment adherence, reduce eczema severity, and enhance psychosocial outcomes. These interventions are particularly valuable in primary care to support self-management and address the chronic nature of eczema.
Bosma et al. (2020) describe the protocol for the TREAT Registry, a European safety study monitoring dupilumab and other systemic therapies in atopic eczema patients. While systemic treatments are generally reserved for moderate-to-severe refractory cases, emerging real-world data will inform their safety profile and optimal use in pediatric populations.
Lancaster et al. (2024) highlight the importance of integrated pediatric primary care models that incorporate behavioral health and dermatology collaboration, facilitating comprehensive eczema management and addressing comorbidities such as anxiety or sleep disturbance.
Ridd et al. (2019) explore the feasibility of allergy testing in children with eczema, noting that while food allergies may exacerbate symptoms in a subset, routine allergy screening is not universally recommended and should be individualized based on clinical history.
Caveats and uncertainty
Topical treatments require consistent application and patient/caregiver education to achieve optimal outcomes; poor adherence remains a significant barrier. Long-term safety data on newer topical agents in young children are limited.
The role of allergy testing in eczema management is still debated, with insufficient evidence to support routine screening absent clear clinical indicators.
Systemic therapies, including biologics like dupilumab, are promising but currently limited by cost, access, and the need for specialist oversight. Long-term safety and efficacy data in diverse pediatric populations are still accruing.
Psychological interventions vary widely in format and intensity, and their implementation in busy primary care settings may be challenging without additional resources.
How this may change practice
Primary care clinicians should prioritize early initiation of topical corticosteroids or calcineurin inhibitors tailored to disease severity and affected sites, coupled with clear instructions to improve adherence.
Incorporating structured educational and psychological support within primary care or via referral can enhance disease control and family coping.
Clinicians should individualize allergy testing decisions, reserving them for cases with suggestive histories or refractory eczema.
For severe or treatment-resistant eczema, timely referral to dermatology for consideration of systemic therapies including dupilumab is warranted, with ongoing monitoring aligned with emerging safety data.
Integrated care approaches that address both dermatologic and psychosocial aspects may optimize outcomes and reduce healthcare utilization.